Cynda issued a profit warning, expecting a year-on-year increase of 2807.87% to 3211.74% in net profit attributable to the parent company for the first three quarters
Cynda expects that the net profit attributable to the parent company in the first three quarters of 2025 will increase by 2807.87% to 3211.74% year-on-year, reaching between 180 million and 205 million yuan. The main reasons include the rise in market prices of its flagship product, oxazolone, and the sales growth of the new product series, pyrazole quinozole. In addition, the company has improved operational efficiency and gross profit margin through operational reforms and gross profit distribution plans
According to the Zhitong Finance APP, Cynda (603086.SH) announced a performance forecast for the first three quarters, expecting a net profit attributable to shareholders of the listed company to reach between 180 million and 205 million yuan for the first three quarters of 2025. This represents an increase of 173.8099 million to 198.8099 million yuan compared to the same period last year (6.1901 million yuan), a year-on-year increase of 2,807.87% to 3,211.74%.
The main reasons for the performance change this period are: the market price of the company's main product, oxazolone, has significantly increased compared to the same period last year, and the newly developed product series, pyrazole quinozole, achieved sales this year, driving the growth of the company's product gross profit margin; the company is promoting operational reforms, implementing a gross profit distribution plan, fully mobilizing the enthusiasm of various units, and implementing various cost control measures, leading to a continuous improvement in operational efficiency
